NCT01248871

"Volatile Anesthetic Protection Of Renal Transplants: VAPOR-1-trail

Completed NA Last updated 16 April 2024

What this trial tests

NA trial testing procedure:sevoflurane-remifentanil/sufentanil in Kidney Donation/Transplantation in 120 participants. Completed in 1 October 2012.

Timeline

1 September 2010

Primary endpoint
1 October 2012

1 October 2012

Quick facts

Lead sponsor	University Medical Center Groningen
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	prevention
Enrollment	120
Start date	1 September 2010
Primary completion	1 October 2012
Estimated completion	1 October 2012
Sites	1 location across Netherlands

Drugs / interventions tested

• procedure:sevoflurane-remifentanil/sufentanil — full drug profile →
• volatile agent only during reperfusion — full drug profile →
• propofol-remifentanil/sufentanil — full drug profile →

Conditions studied

• Kidney Donation/Transplantation — all drugs for Kidney Donation/Transplantation →

Sponsor

University Medical Center Groningen

Who can join

Adults 18 to 80, any sex, with Kidney Donation/Transplantation. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

• To compare the renal protective properties of two currently used anaesthetic techniques
  Time frame: participants will be followed for the duration of hospital stay

Sponsor's own description

To compare the renal protective properties of two currently used anaesthetic techniques - a sevoflurane-remifentanil/sufentanil combination with a propofol-remifentanil/sufentanil combination for anaesthesia in patients undergoing living donor kidney donation/transplantation.

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

1. Propofol-based anaesthesia versus sevoflurane-based anaesthesia for living donor kidney transplantation: results of the VAPOR-1 randomized controlled trial.
   Nieuwenhuijs-Moeke GJ, Nieuwenhuijs VB, Seelen MAJ, Berger SP, et al · · 2017 · cited 39× · PMID 28510740 · DOI 10.1093/bja/aex057
2. Preemptively and non-preemptively transplanted patients show a comparable hypercoagulable state prior to kidney transplantation compared to living kidney donors.
   Nieuwenhuijs-Moeke GJ, van den Berg TAJ, Bakker SJL, van den Heuvel MC, et al · · 2018 · cited 9× · PMID 30011293 · DOI 10.1371/journal.pone.0200537
3. Peri-Operative Kinetics of Plasma Mitochondrial DNA Levels during Living Donor Kidney Transplantation.
   Kroneisl M, Spraakman NA, Koomen JV, Hijazi Z, et al · · 2023 · cited 3× · PMID 37686384 · DOI 10.3390/ijms241713579
4. Systemic and Renal Dynamics of Free Sulfhydryl Groups during Living Donor Kidney Transplantation.
   Spraakman NA, Coester AM, Bourgonje AR, Nieuwenhuijs VB, et al · · 2022 · cited 3× · PMID 36077183 · DOI 10.3390/ijms23179789
5. Urinary Biomarkers in a Living Donor Kidney Transplantation Cohort-Predictive Value on Graft Function.
   Huisman GJJ, Spraakman NA, Koomen JV, Talsma AM, et al · · 2023 · cited 1× · PMID 36982720 · DOI 10.3390/ijms24065649
6. Effect of a Laparoscopic Donor Nephrectomy in Healthy Living Kidney Donors on the Acute Phase Response Using Either Propofol or Sevoflurane Anesthesia.
   Brattinga B, Huang H, Maslau S, Thorne AM, et al · · 2025 · PMID 40508008 · DOI 10.3390/ijms26115196